Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T16:03:32.747Z.
Calculation as of: 2026-10-06T16:03:32.747Z.
Quote observation: 2026-10-06T16:00:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a2c27257439ebc7e0324c407d6ec5b5d27bfaa5dcb56832ff3962ee146363265
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$108.84M
EBITDA Yield
N/A
TTM Avg
6.77%
3Y Avg
6.77%
5Y Avg
6.77%
Market Cap
$108.11M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$110.43M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$110.73M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$106.08M
EBITDA Yield
N/A
TTM Avg
5.35%
3Y Avg
4.92%
5Y Avg
4.17%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immunic, Inc. (IMUX) | $109.02M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $108.84M | N/A | 6.77% | 6.77% | 6.77% |
| Outlook Therapeutics, Inc. (OTLK)vs › | $109.34M | N/A | N/A | N/A | N/A |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.11M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $110.33M | N/A | N/A | N/A | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $110.43M | N/A | N/A | N/A | N/A |
| BGM Group Ltd. (BGM)vs › | $111.27M | N/A | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $110.73M | N/A | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.08M | N/A | 5.35% | 4.92% | 4.17% |
| Definitive Healthcare Corp. (DH)vs › | $105.27M | 204.11% | 162.58% | 142.94% | 38.81% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
